abaloparatide

 

Topic mentions per year

Topic mentions per year

2009-2018
051020092018

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
There are a number of effective treatments for osteoporosis but most are in the antiresorptive class of compounds. Abaloparatide… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
Is this relevant?
2017
2017
Abaloparatide is a novel 34 amino acid peptide selected to be a potent and selective activator of the parathyroid hormone… (More)
  • table 1
  • table 2
Is this relevant?
2017
2017
Daily subcutaneous (SC) injections of the investigational drug abaloparatide-SC (80 mcg) for 18 months significantly decrease the… (More)
Is this relevant?
2017
2017
Prolonged treatment with human parathyroid hormone (hPTH) in rats results in development of bone tumors, though this finding has… (More)
  • table 1
  • table 2
  • figure 1
  • table 3
  • figure 2
Is this relevant?
Review
2017
Review
2017
Abaloparatide (Tymlos™) is a synthetic peptide analogue of human parathyroid hormone-related protein that was developed by Radius… (More)
Is this relevant?
Review
2017
Review
2017
The treatment of osteoporosis is generally either by inhibition of bone resorption with antiresorptive agents or by stimulation… (More)
  • figure 1
  • figure 3
  • figure 4
Is this relevant?
2016
2016
IMPORTANCE Additional therapies are needed for prevention of osteoporotic fractures. Abaloparatide is a selective activator of… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
2016
2016
The PTH receptor type 1 (PTHR1) mediates the actions of two endogenous polypeptide ligands, PTH and PTHrP, and thereby plays key… (More)
Is this relevant?
2015
2015
CONTEXT Abaloparatide is a novel synthetic peptide analog of parathyroid hormone-related protein (PTHrP) that is currently being… (More)
Is this relevant?
2015
2015
Teriparatide administered by daily subcutaneous injection, was approved in the United States in 2002, and has been the only… (More)
Is this relevant?